Shopping Cart
- Remove All
- Your shopping cart is currently empty
GNE-900 is an ATP-competitive ChK1 inhibitor with selective and oral activity.GNE-900 inhibits ChKl and ChK2 with IC50 values of 0.0011 and 1.5 µM, respectively.GNE-900 enhances DNA damage and induces apoptosis. GNE-900 has antitumor activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $58 | In Stock | |
5 mg | $139 | In Stock | |
10 mg | $223 | In Stock | |
25 mg | $396 | In Stock | |
50 mg | $595 | In Stock | |
100 mg | $913 | In Stock |
Description | GNE-900 is an ATP-competitive ChK1 inhibitor with selective and oral activity.GNE-900 inhibits ChKl and ChK2 with IC50 values of 0.0011 and 1.5 µM, respectively.GNE-900 enhances DNA damage and induces apoptosis. GNE-900 has antitumor activity. |
Targets&IC50 | Chk2:1.5 μM, Chk1:0.0011 μM |
In vitro | GNE-900 (1 µM; 1-48 h; HT-29 cells) induces apoptosis and enhances cleaved PARP expression when combined with gemcitabine (50 nM) in HT-29 cells.[1] |
In vivo | GNE-900 (2.5-40 mg/kg, p.o., once; Sprague-Dawley rats) combined with gemcitabine (120 mg/kg) reduced tumor volume and increased DNA damage and γ-H2AX expression levels in rats.[1] |
Alias | GNE900, GNE 900 |
Molecular Weight | 367.45 |
Formula | C23H21N5 |
Cas No. | 1200126-26-6 |
Smiles | C(#N)C=1C=C2C=3C(NC2=CN1)=NC=C(C3)C4=CC=C(CN5CCCCC5)C=C4 |
Storage | store at low temperature,keep away from direct sunlight | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 3.85 mg/mL (10.47 mM), Sonication is recommended. ![]() | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.